Average Co-Inventor Count = 2.54
ph-index = 14
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. University of California (36 from 15,458 patents)
2. Agensys, Inc. (5 from 196 patents)
3. City of Hope (2 from 639 patents)
4. Other (1 from 832,680 patents)
5. University (1 from 8 patents)
38 patents:
1. 9527919 - High affinity anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting and detection
2. 9470689 - N-cadherin: target for cancer diagnosis and therapy
3. 9388247 - Antibodies against cancer target block tumor growth, angiogenesis and metastatis
4. 8940871 - Engineered anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting
5. 8940298 - High affinity anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting and detection
6. 8759006 - PSCA: prostate stem cell antigen and distinguishing androgen receptor negative prostate cancer from benign prostatic hyperplasia
7. 8703920 - Fully human antibodies against N-cadherin
8. 8663635 - N-cadherin: target for cancer diagnosis and therapy
9. 8524460 - PSCA: prostate stem cell antigen and uses thereof
10. 8404817 - Humanized anti-prostate stem cell antigen monoclonal antibody
11. 8088908 - Humanized anti-prostate stem cell antigen monoclonal antibody
12. 7595431 - Mouse models of human prostate cancer
13. 7527786 - Methods for inhibiting the growth of cancer cells expressing PSCA
14. 7485296 - PSCA: prostate stem cell antigen and uses thereof in pancreatic cancer
15. 7462691 - Mouse prostate stem cell antigen and uses thereof